- Incannex Healthcare (IHL) has engaged Procaps S.A. to manufacture its soft-gel capsules in preparation for clinical trials
- The agreement between IHL and Procaps is effective immediately and will see Procaps manufacture the IHL-42X soft gel capsules for treating obstructive sleep apnoea
- The initial agreement spans across twelve months and will remain in place for as long as required for clinical trials
- Meanwhile, the proof-of-concept Phase 2 clinical trial is underway to assess the treatment, with patient dosing expected to be completed in the December quarter
- Incannex Healthcare is up 4.17 per cent trading at 37.5 cents
Incannex Healthcare (IHL) has engaged a company to manufacture its soft-gel capsules in preparation for upcoming clinical trials.
The company has engaged Procaps S.A. to develop and manufacture IHL’s cannabinoid drug for treating obstructive sleep apnoea, IHL-42X.
Incannex Healthcare CEO and Managing Director Joel Latham said he was pleased to be partnering with Procaps.
“Partnering with Procaps will help us formulate the best possible product for IHL-42X,” he said.
“Procaps will supply our clinical trial programs but can also quickly ramp up production for commercial supply upon successful clinical trial outcomes.”
Procaps has already developed over 500 formulations for both pharmaceutical and nutritional products, stated it has reached over 50 markets globally.
Procaps is thought to be equipped to provide commercial manufacture of the capsules at scale.
The company offers patented Unigel technology, which consists of an apparatus and process for encapsulating capsules or other solid dosage form within capsules.
The IHL-42X soft gel capsules will be pharmaceutical-grade and used in phase 2, phase 3 and open label clinical trials.
The agreement between IHL and Procaps is effective immediately and will remain in place for as long as supply of IHL-42X soft gel capsules are required for clinical trial purposes.
The agreement spans across twelve months, with four-month firm orders required for Procaps’ planning purposes.
Meanwhile, proof-of-concept Phase 2 clinical trial are underway to assess IHL-42X and its effectiveness at reducing the Apnea Hypopnea Index.
Patient dosing is expected to be completed in the December quarter of 2021, with results due in first quarter of 2022.
Incannex Healthcare was up 4.17 per cent, trading at 37.5 cents at 11:30 am AEDT.